SCHEDULE 13G/A: SCHEDULE 13G/A – Description
Allogene Therapeutics, Inc.
SCHEDULE 13G/A: SCHEDULE 13G/A – Description
Allogene Therapeutics, Inc.
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics…
ARS: An annual report to security holders
Allogene Therapeutics, Inc.
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif. , April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™…